APE (APE) News
Track canonical SquawkNews coverage tagged to APE, APE. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 18 indexed stories across 9 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Switzerland's Addex Therapeutics Q2 net loss narrows on decline in R&D expenses
OverviewOutlookResult DriversCompany press release:Key DetailsReuters Recommended ReadsFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact re
EARNINGS | Sep 28, 2026, 05:10 AM UTC
L
Addex Therapeutics (APE) Posts H1 Results; Raises $2.8M Post Period
Addex reported H1 2026 results: cash CHF 0.8M at June 30 and stable loss per share at CHF 0.03. Post period, it sold 52.97M shares for CHF 2.3M ($2.8M). It regained all rights to its GABAB PAM SUD program and advances a
EQUITY | Sep 28, 2026, 05:01 AM UTC
L
Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate Update
Ad Hoc Announcement Pursuant to Art. 53 LRGeneva, Switzerland, September 28, 2026 - Addex Therapeutics (SIX and NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small mo
NEWS | Sep 28, 2026, 05:00 AM UTC
L
Addex Therapeutics (APE) Regains Global Rights to GABAB PAM Portfolio
Addex Therapeutics regained full global rights to all GABAB positive allosteric modulator assets from Indivior, including a candidate for substance use disorders, and will evaluate new partnerships or internal advancemen
NEWS | Sep 25, 2026, 05:08 AM UTC
L
Addex Regains Rights to GABAB Positive Allosteric Modulator Portfolio from Indivior
Addex Regains Rights to GABAB Positive Allosteric Modulator Portfolio from Indivior
NEWS | Sep 25, 2026, 05:00 AM UTC
L
Addex Therapeutics to Report 2026 Half-Year Financial Results and Host Conference Call on September 28, 2026
Geneva, Switzerland, September 24, 2026 - Addex Therapeutics (SIX and NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurologi
EARNINGS | Sep 24, 2026, 05:00 AM UTC
M
Eagers Automotive invests in Zagame Automotive Group
Eagers Automotive Limited (ASX: APE) announced a strategic investment into Zagame Automotive Group.
MNA | Sep 10, 2026, 01:36 AM UTC
L
Eagers Expects Investment to Immediately Boost Own Earnings
Eagers Expects Investment to Immediately Boost Own Earnings
EARNINGS | Sep 09, 2026, 10:53 PM UTC
L
Eagers will complete Zagame deal by end-November
MNA | Sep 09, 2026, 10:53 PM UTC
L
Eagers: Zagame Automotive Represents 14 Prestigious Brands Across Melbourne, Adelaide
Eagers: Zagame Automotive Represents 14 Prestigious Brands Across Melbourne, Adelaide
EQUITY | Sep 09, 2026, 10:51 PM UTC
L
Eagers to operate as a JV with founder Bobby Zagame
MNA | Sep 09, 2026, 10:51 PM UTC
M
Eagers Automotive to buy 50% interest in Zagame Automotive Group
Eagers Automotive agreed to buy a 50% interest in Zagame Automotive Group, according to the report.
MNA | Sep 09, 2026, 10:50 PM UTC
L
UBS cuts Eagers Automotive price target by 4.1% to A$22.00
UBS cut its price target for Eagers Automotive by 4.1% to A$22.00 per share.
EQUITY | Sep 07, 2026, 11:28 PM UTC
L
Macquarie raises Eagers Automotive price target 0.4% to A$26.60
Macquarie raised its price target for Eagers Automotive by 0.4% to A$26.60 per share.
EQUITY | Aug 28, 2026, 12:36 AM UTC
L
Eagers Automotive price target cut by Morgans to A$26.30
Morgans cut its price target for Eagers Automotive by 3.5% to A$26.30 per share.
EQUITY | Aug 27, 2026, 11:40 PM UTC
L
Bell Potter cuts Eagers Automotive price target to A$27.50
Bell Potter cut its Eagers Automotive price target 1.8% to A$27.50 a share.
EQUITY | Aug 27, 2026, 10:52 PM UTC
M
Eagers Automotive posts half-year net profit attributable of A$126.6 million
Eagers Automotive reported half-year net profit attributable of A$126.6 million.
EQUITY | Aug 27, 2026, 01:43 AM UTC
L
APE highlights record revenue and profit growth
APE reported record revenue and profit growth, strong margins, and a robust outlook amid industry transformation.
EARNINGS | Aug 26, 2026, 10:59 PM UTC